UPDATE: Morgan Stanley Reiterates on Express Scripts on Potential Positive Sign for Renewal

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Express Scripts (NASDAQ: ESRX ), but removed the $70.00 price target. In the report, Morgan Stanley noted, “The Department of Defense published a new rule in the Federal Register requiring members of the TRICARE